The efficacy and safety of omalizumab in the treatment of asthma: an overview of systematic reviews and meta analyses.

Front Med (Lausanne) · 2025 · PMC12855417 · PMID 41625732

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

For pediatric asthma patients, studies ( 37 , 38 ) showed that although omalizumab reduced ICS dose, the clinical relevance did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.